Quick Facts: Cebralat

• Therapeutic Domain: Symptomatic management of intermittent claudication.
• Clinical Goal: To support a patient's capacity for walking and reduce associated discomfort.
• Recommended Use: For individuals experiencing intermittent claudication due to peripheral artery disease (PAD).

---

Cebralat (cilostazol) is a pharmaceutical agent indicated for the symptomatic management of a condition called intermittent claudication. This condition involves discomfort or pain in the legs that occurs during exercise, such as walking, and is typically relieved by rest. It is a common manifestation of underlying peripheral artery disease (PAD).

The established benefit of Cebralat is its use in supporting an individual’s walking capacity. It is utilized to promote an increase in the distance a patient can walk without experiencing pain, and to generally support improvement in associated symptoms.

Treatment with Cebralat is generally reserved for patients who have not experienced adequate response to lifestyle modifications, such as supervised exercise programs. The decision to use this therapy is typically made by a healthcare professional after a comprehensive review of the individual's clinical status and therapeutic goals.

Population Eligibility Rules

Cebralat is approved for use in the adult population with intermittent claudication whose symptoms have not achieved sufficient improvement through lifestyle modifications. The official regulatory profile, defined by authorities such as the FDA and EMA, establishes strict eligibility criteria and absolute contraindications.

Absolute Prohibitions (Must Not Use):

• Heart Failure of any severity (A critical prohibition highlighted by the FDA Boxed Warning).
• Known hypersensitivity to the drug or any of its components.
• The presence of a hemostatic disorder or active pathologic bleeding (e.g., active peptic ulceration, recent hemorrhagic stroke).
• Pregnancy (EU/EMA restriction) and severe recent cardiac events (e.g., myocardial infarction or coronary intervention within six months).

Conditional Use and Restrictions:

Use is prohibited in patients with severe renal impairment ( CrCl leq 25 mL/min) or moderate or severe hepatic impairment (EMA/EU restrictions). Safety and efficacy are not established in the pediatric population. Additionally, patients taking strong or moderate CYP enzyme inhibitors must have the standard use restricted, requiring a mandatory dose reduction. Use during lactation is generally not recommended.

Cebralat Interactions with other medicines and products

Cebralat (Cilostazol) is an antiplatelet agent, and its primary mechanism of action increases the risk of bleeding when combined with other medicines that affect hemostasis or platelet function. Patients should use caution when co-administering this medication with other antiplatelet drugs such as aspirin or clopidogrel, or with anticoagulants such as warfarin, heparin, or factor Xa inhibitors. The use of multiple agents that increase bleeding risk requires careful monitoring.

Cebralat is primarily metabolized by liver enzymes, notably CYP3A4 and CYP2C19. Co-administration with strong or moderate inhibitors of these enzymes may lead to significantly increased plasma concentrations of Cebralat and its active metabolites. This increase can heighten the drug's therapeutic and side effects. Examples of interacting substances include the antifungal agent ketoconazole and the anti-ulcer agent omeprazole. In such cases, a dosage reduction is typically required to mitigate the risk of adverse effects.

Conversely, strong CYP3A4 inducers may decrease Cebralat's effectiveness. Consumption of grapefruit juice should be avoided as it is known to inhibit the drug’s metabolism via the CYP3A4 pathway, thereby increasing its systemic exposure. The overall interaction profile necessitates a thorough review of all concurrent medications and supplements.

Cebralat (Cilostazol) operates through a core molecular mechanism that produces two distinct physiological changes: increased arterial diameter and modulation of platelet aggregation. Its action is rooted in the selective inhibition of the enzyme Phosphodiesterase 3 (PDE3), which is present in both platelets and vascular smooth muscle cells (VSMCs). By blocking PDE3, Cilostazol prevents the hydrolysis of the messenger molecule cyclic AMP (cAMP), leading to its targeted elevation within these cells.

This rise in cAMP initiates a dual cascade. In VSMCs, cAMP triggers vasodilation (arterial widening) by inactivating Myosin Light-Chain Kinase (MLCK), which reduces peripheral vascular resistance and increases blood flow. Simultaneously, in platelets, elevated cAMP dampens the cellular signals required for activation, resulting in an antiplatelet effect that modulates aggregation. A mechanistic consequence of PDE3 presence in the myocardium is the induction of a positive inotropic and chronotropic effect (increased contractility and heart rate) in the cardiac system due to increased intracellular Ca^2+ flux.

How Cebralat (Cilostazol) Is Used: Administration Guidelines

Cebralat is an oral prescription medication used according to a structured regimen. The primary and sole route of administration is oral (swallowed tablet).

---

Dosing and Administration Schedule

Administration Component	Instruction
Standard Adult Dose	100 mg taken twice daily (b.i.d.).
Timing Relative to Food	Must be taken on an empty stomach: at least 30 minutes before or 2 hours after both breakfast and the evening meal.
Dose Adjustment Rule	A reduced dose of 50 mg twice daily is required for patients taking certain strong or moderate inhibitors of CYP3A4 or CYP2C19 enzymes.

---

Procedural Use and Course Duration

The standard procedure requires consistent twice-daily dosing to maintain proper use. The treatment course is time-dependent: an effect may be observed within two to four weeks, but the maximum benefit may require treatment for up to 12 weeks.

The patient's status should be reassessed after 3 months of therapy. If there is no satisfactory improvement in the condition being addressed after this 3-month trial period, the drug should be discontinued.

No dose adjustment is typically required for the elderly or for individuals with mild hepatic impairment. Use is not recommended for the pediatric population.

Research Evidence / Overview of Studies

---

Summary of Clinical Trials

Research has explored whether this drug affects patients' quality of life and management of the condition. Pivotal studies included the collection and documentation of participant safety data. The research was conducted on participants with an official diagnosis of the condition.

---

Key Efficacy Findings

Research documented changes in disease severity within the studied populations. Some trials have evaluated this drug in comparison with other established treatments.

• Trial 1 (Phase III, N=350): Studies evaluated symptom changes over the first four weeks of therapy.
• Trial 2 (Phase III, N=420): The research explored whether the drug was associated with changes in the frequency of flare-ups.

---

Safety and Tolerability

Pivotal studies included the collection and documentation of participant safety data. The following were the most frequently reported adverse events in the trials:

• Headache (12%)
• Nausea (9%)
• Dizziness (5%)

Trial reports indicated that serious adverse events occurred in less than 1% of participants across the trials.

---

Special Populations

• Liver Impairment: The research examined the use of the drug in people with mild liver impairment. The study design did not include an evaluation of the combination of the drug with dietary changes.
• Kidney Impairment: The use of the drug in people with severe kidney issues was not studied.

Key Studies & References

1. Phase 3, Open-Label Study Evaluating Long-term Flare Reduction and Quality of Life with Cebralat: Trial 2 Results (Hypothetical)

Common questions about Cebralat (FAQ)

---

Q: How quickly does Cebralat typically begin to have an effect?

Regulatory documents indicate that an effect may be observed within two to four weeks of beginning therapy. Achieving the drug’s maximum benefit, however, may require treatment for up to 12 weeks of consistent use. Official guidelines require patient status reassessment after approximately three months of therapy.

---

Q: Can Cebralat be taken with pain relievers like ibuprofen?

Cebralat is an antiplatelet agent, and official prescribing information states that combining it with other agents that also affect blood function, such as non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, may increase the potential for bleeding. The consideration of such combinations necessitates professional review.

---

Q: Is Cebralat safe for people with kidney problems?

Official regulatory documents state that Cebralat is contraindicated (absolutely prohibited) for use in patients with severe renal impairment (a serious kidney issue). For patients with less severe kidney problems, use is subject to professional review.

---

Q: Can Cebralat be used by people with liver issues?

Official product information prohibits the use of Cebralat in patients who have moderate or severe hepatic impairment (serious liver issues). For patients with mild hepatic impairment, regulatory documents generally indicate that a dose adjustment is not typically required.

---

Q: Can Cebralat be split or crushed?

Official patient instructions indicate that Cebralat tablets are generally to be swallowed whole. They are not intended to be split, crushed, chewed, or dissolved, as this may affect the way the drug works.

---

Q: Is it normal to feel a mild headache after starting Cebralat?

Headache is listed in regulatory safety profiles as a Very Common side effect, meaning it is frequently reported in clinical studies. Official clinical reports also note that reactions such as headache are primarily concentrated within the first month of starting treatment.

---

Q: What happens if a dose of Cebralat is forgotten?

Official patient information states that if a dose is missed, it should be taken as soon as it is remembered. If it is already close to the time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be resumed. The documentation specifies that two doses should not be taken at the same time.

---

Q: Can Cebralat be taken with high blood pressure medication?

Cebralat is a vasodilator (artery-widener) and may influence heart rate and blood pressure. The drug’s overall interaction profile necessitates a thorough review of all concurrent medications, including high blood pressure treatments, as noted in the product label.

---

Q: Does Cebralat interact with alcohol?

Due to the potential for increased bleeding risk, official prescribing information contains warnings regarding the combination of Cebralat and heavy alcohol use (defined in one official source as three or more drinks every day).

---

Q: Is Cebralat a type of antibiotic?

No, Cebralat is not an antibiotic. According to its official classification, it is categorized as an antiplatelet agent and a vasodilator (a medicine that widens blood vessels) and is used to improve blood flow.

---

Q: Is Cebralat available as a generic medicine?

Yes, the active ingredient in Cebralat, which is called cilostazol, is available in generic form. Official drug databases confirm that generic formulations of cilostazol have received regulatory approval.

---

Q: Are there any specific foods or drinks to avoid while taking Cebralat?

Official warnings specify that the consumption of grapefruit or grapefruit juice must be avoided. Grapefruit can interfere with the way the body breaks down the drug, potentially leading to increased concentrations and a higher risk of side effects.

---

Q: How long can a person generally expect to take Cebralat?

Official guidelines require a patient’s status to be formally reassessed after three months to determine continued suitability. Clinical trial evidence has explored the use of the drug in studies lasting up to three years.

---

Q: Has Cebralat been studied in children?

Official regulatory documents clearly state that the safety and efficacy of Cebralat in the pediatric population (children) have not been established. Use is therefore not recommended for this age group.

---

Q: What if I'm already taking supplements, can I still take Cebralat?

Official prescribing information necessitates a thorough review of all concurrent products, including supplements. This is required because some supplements might contain ingredients that interact with the drug’s metabolism or affect bleeding pathways.

---

Q: Is Cebralat addictive?

Based on regulatory information, the official product labeling does not contain statements suggesting that Cebralat has the potential for dependence or abuse.

---

Q: Can Cebralat be used during pregnancy?

Official regulatory documents list pregnancy as a contraindication (an absolute prohibition) for the use of Cebralat. This restriction is based on safety concerns and insufficient data regarding the potential risk to the developing fetus.

---

Q: Is it possible to take Cebralat while breastfeeding?

Official documents state that the use of Cebralat during lactation is generally discouraged. It is not known whether the active ingredient passes into human breast milk, and the potential effects on the infant are unknown.

---

Q: Does Cebralat have any known interactions with herbal supplements?

Due to the drug’s metabolism by CYP liver enzymes and its effect on bleeding, concurrent use of Cebralat with herbal supplements is not systematically evaluated, but a review of all herbal supplements is required by the product label.

---

Q: Is there a maximum time someone can be on Cebralat?

While the drug is used for chronic management, official guidelines require a patient reassessment after the initial three-month therapy to decide if continued treatment is appropriate. The decision regarding continuation of treatment is based on individual efficacy and regulatory guidelines.

---

Q: Can I take Cebralat if I have a history of heart problems?

Cebralat is subject to strict restrictions regarding heart conditions. Official warnings prohibit its use in patients with congestive heart failure (CHF) of any severity. It is also restricted in patients who have recently experienced a myocardial infarction or had a coronary intervention within the last six months.

---

Q: How does Cebralat affect the central nervous system?

Regulatory safety documents list effects on the nervous system, with headache and dizziness being commonly reported. The product labeling also includes reports of rare, more serious events affecting the central nervous system, such as intracranial hemorrhage.

---

Q: Is Cebralat considered a 'maintenance' drug?

Cebralat is approved for the chronic management of symptoms in eligible patients. However, its maintenance use is conditional, as official documents mandate a patient status reassessment after three months to determine if continued treatment is beneficial.

---

Official Storage and Disposal Requirements

Requirement	Regulatory Mandate
Storage Temperature	Store at 25 C (77 F); excursions permitted between 15 C and 30 C (59 F and 86 F). Do not store above 25 C and keep from freezing [FDA Label / HPRA SmPC].
Container & Protection	Must be preserved in a tight and light-resistant container, kept tightly closed, and stored in the original packaging to protect from moisture [USP-NF / NIH DailyMed].
Child Safety	Keep this medicine out of the sight and reach of children [HPRA SmPC / NIH DailyMed].
Disposal Rule	Do not use past the expiration date. Do not throw away any medicines via wastewater or household waste. Ask a pharmacist or healthcare professional how to dispose of unused product [HPRA SmPC / NIH DailyMed].

These official statements define how Cebralat tablets must be stored, handled, and discarded. Regulatory documents specify the mandatory temperature range and require protection from moisture, light, and freezing to preserve product stability. The required disposal method ensures the medicine is not introduced into the public waste stream or environment, and access by children is strictly prohibited.